Amneal Pharmaceuticals, Inc. reported Q2 2025 net revenue of $725 million, with a GAAP net income of $22 million and diluted income per share of $0.07. Adjusted EBITDA was $184 million, with adjusted diluted EPS of $0.25. Full year 2025 guidance has been raised, and debt refinancing has reduced interest costs and extended maturities to 2032.

Specialty net revenue saw a 23% increase driven by key branded products in Q2 2025. Affordable Medicines net revenue increased by 1%, while AvKARE net revenue decreased by 4%. Net income attributable to Amneal Pharmaceuticals, Inc. was $22 million, reflecting higher revenue and gross profit.

Adjusted EBITDA in Q2 2025 was $184 million, a 13% increase from the same quarter in 2024. Diluted income per share was $0.07, an increase from $0.02 in Q2 2024. Adjusted diluted earnings per share for Q2 2025 was $0.25, a 56% increase from Q2 2024.

Amneal Pharmaceuticals, Inc. raised its full year 2025 financial guidance. Net revenue is expected to be between $3.0 billion and $3.1 billion, with adjusted EBITDA between $665 million and $685 million. Adjusted diluted EPS is forecasted to be between $0.70 and $0.75.

Debt refinancing efforts by Amneal Pharmaceuticals, Inc. have optimized the company’s capital structure. A comprehensive refinancing plan has reduced interest costs and extended maturities to 2032. The successful refinancing will result in substantial interest cost savings for the company.

Amneal Pharmaceuticals, Inc.’s non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted operating cash flow, and net leverage, provide a supplemental measure of the company’s performance not required by GAAP. These measures help evaluate and manage the company’s operations effectively.

Read more at GlobeNewswire: Amneal Reports Second Quarter 2025 Financial Results